CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

Expressed by cancer stem cells of various epithelial cell origins, CD133 is an attractive therapeutic target for cancers. Autologous chimeric antigen receptor-modified T-cell directed CD133 (CART-133) was first tested in this trial. The anti-tumor specificity and the postulated toxicities of CART-13...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yao, Chen, Meixia, Wu, Zhiqiang, Tong, Chuan, Dai, Hanren, Guo, Yelei, Liu, Yang, Huang, Jianhua, Lv, Haiyan, Luo, Can, Feng, Kai-chao, Yang, Qing-ming, Li, Xiao-lei, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993480/
https://www.ncbi.nlm.nih.gov/pubmed/29900044
http://dx.doi.org/10.1080/2162402X.2018.1440169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993480/
https://www.ncbi.nlm.nih.gov/pubmed/29900044
http://dx.doi.org/10.1080/2162402X.2018.1440169

Ejemplares similares